Dr. Philip J. Bergman Joins ELIAS Animal Health's Scientific Advisory Board

Dr. Philip J. Bergman Appointed to ELIAS Animal Health Advisory Board

ELIAS Animal Health has taken a significant step forward in veterinary oncology by announcing the addition of Dr. Philip J. Bergman, DVM, PhD, DACVIM (Oncology), to its Scientific Advisory Board. With his extensive background and skills, Dr. Bergman is set to play a pivotal role in shaping the future of cancer treatment in veterinary medicine.

A Leader in Veterinary Oncology

Dr. Bergman's experience in veterinary oncology is both extensive and impressive. He has dedicated much of his career to advancing cancer treatment options for companion animals, focusing primarily on innovative immunotherapies. His work includes notable contributions to the development of cutting-edge treatments, such as ONCEPT®, a licensed canine melanoma vaccine that has changed the landscape of veterinary cancer care.

Before joining ELIAS Animal Health, he served as the Global Director of Clinical Studies for Mars Veterinary Health and VCA, where he contributed significantly to developing emerging treatment modalities. His academic endeavors include roles as an adjunct faculty member at the Memorial Sloan-Kettering Cancer Center and past leadership positions like Chair of the American College of Veterinary Internal Medicine Board of Regents and President of the Veterinary Cancer Society.

Dr. Bergman's educational journey commenced at Colorado State University, where he completed veterinary school, followed by an internship at Kansas State University. He then pursued a medical oncology residency at Colorado State University, and furthered his knowledge with a PhD Fellowship in human cancer biology at the prestigious M.D. Anderson Cancer Center in Houston.

Commitment to Advancing Cancer Therapies

Tammie Wahaus, CEO of ELIAS Animal Health, expressed enthusiasm regarding Dr. Bergman's appointment, emphasizing the value of his deep knowledge and leadership in veterinary oncology. 'Dr. Bergman's expertise will be invaluable as we continue to advance our immunotherapeutic solutions for pets with cancer,' she stated. His insights are expected to guide ELIAS in refining and proliferating its innovative cancer treatment protocols, particularly in expanding its adoptive cell therapy platform.

In Dr. Bergman’s own words regarding his new role, he expressed excitement about joining the team at ELIAS: 'I am particularly excited and honored to be joining the ELIAS Animal Health Scientific Advisory Board. Their recent USDA license for canine osteosarcoma represents the first of many ELIAS-led advancements to come in veterinary cancer immunotherapy.'

ELIAS Animal Health has recently achieved full licensing from the USDA for its ELIAS Cancer Immunotherapy (ECI®), which is now accessible at over 100 authorized treatment locations across the United States.

The Future of Veterinary Cancer Treatment

With Dr. Bergman on board, ELIAS Animal Health is poised to lead the way in revolutionizing cancer treatment strategies for pets. Their aggressive approach towards research and development, coupled with new perspectives from a seasoned expert like Dr. Bergman, could significantly enhance clinical outcomes for animals facing cancer.

For further information about ELIAS Animal Health and their innovative approaches to cancer care, visit www.eliasanimalhealth.com.

About ELIAS Animal Health

ELIAS Animal Health is at the forefront of veterinary medical biotechnology, focusing on the advancement of immunotherapies designed for treating cancer in pets. Their ongoing commitment to improving the treatment landscape provides hope for better clinical outcomes for companion animals fighting this serious disease. Explore more about their initiatives and therapeutic pipelines on their website.